Markets:

Overview

News

Currencies

International

Treasuries

Y-mAbs Therapeutics, Inc. - Common Stock (NQ:YMAB)

8.610 UNCHANGED

Last Price Updated: 4:00 PM EDT, Sep 15, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Y-mAbs Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Beyond The Numbers: 4 Analysts Discuss Y-mAbs Therapeutics Stock ↗

November 18, 2024

Via Benzinga

Examining the Future: Y-mAbs Therapeutics's Earnings Outlook ↗

November 07, 2024

Via Benzinga

Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights ↗

October 30, 2024

Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio.

Via Benzinga

Navigating 8 Analyst Ratings For Y-mAbs Therapeutics ↗

September 09, 2024

Via Benzinga

Assessing Y-mAbs Therapeutics: Insights From 5 Financial Analysts ↗

August 13, 2024

Via Benzinga

Why Y-mAbs Therapeutics Stock Got Mashed on Monday ↗

August 12, 2024

The company didn't quite meet expectations for either trailing results or full-year guidance.

Via The Motley Fool

Cracking The Code: Understanding Analyst Reviews For Y-mAbs Therapeutics ↗

March 06, 2024

Via Benzinga

Earnings Scheduled For February 29, 2024 ↗

February 29, 2024

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.

Via Benzinga

Earnings Outlook For Y-mAbs Therapeutics ↗

February 28, 2024

Via Benzinga

Earnings Preview For Y-mAbs Therapeutics ↗

November 10, 2023

Via Benzinga

YMAB Stock Earnings: Y-mAbs Therapeutics Misses EPS, Misses Revenue for Q2 2024 ↗

August 12, 2024

YMAB stock results show that Y-mAbs Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

Via InvestorPlace

Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket ↗

August 12, 2024

Via Benzinga

MSC Industrial Direct, Radius Recycling And 3 Stocks To Watch Heading Into Tuesday ↗

July 02, 2024

Via Benzinga

YMAB Stock Earnings: Y-mAbs Therapeutics Misses EPS, Misses Revenue for Q1 2024 ↗

May 07, 2024

YMAB stock results show that Y-mAbs Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Via InvestorPlace

Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday ↗

March 01, 2024

U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday.

Via Benzinga

Topics Stocks

4 Analysts Have This to Say About Y-mAbs Therapeutics ↗

August 14, 2023

Via Benzinga

Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

March 01, 2024

Shares of Zscaler, Inc. (NASDAQ: ZS) shares fell sharply during Friday’s session following second-quarter results.

Via Benzinga

Why NetApp Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket ↗

March 01, 2024

Shares of NetApp, Inc. (NASDAQ: NTAP) shares rose sharply in today’s pre-market trading after the company reported better-than-expected third-quarter financial results and issued guidance.

Via Benzinga

Analyst Expectations for Y-mAbs Therapeutics's Future ↗

July 25, 2023

Via Benzinga

Where Y-mAbs Therapeutics Stands With Analysts ↗

June 07, 2023

Via Benzinga

B of A Securities Maintains Neutral Rating for Y-mAbs Therapeutics: Here's What You Need To Know ↗

May 15, 2023

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

March 01, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

February 29, 2024

Via Benzinga

Beam Therapeutics Stock Shows Healthy Relative Strength Improvement ↗

February 16, 2024

In a welcome move, Beam Therapeutics stock saw its Relative Strength (RS) Rating rise from 67 to 76 on Friday.

Via Investor's Business Daily

Micro Marvel - Y-Mabs Therapeutics ↗

February 13, 2024

Wall Street projected revenue will grow 26.00% this year and another 18.80% next year. Earnings are estimated to increase 68.90% this year but decrease 8.80% next year.

Via Talk Markets

12 Health Care Stocks Moving In Monday's Intraday Session ↗

January 15, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

January 12, 2024

Via Benzinga

Analyst Upgrades Y-mAbs On Bullish Danyelza Sales Outlook, Improved Visibility ↗

May 10, 2023

Wedbush has upgraded Y-mAbs Therapeutics Inc (NASDAQ: YMAB)to Outperform from Neutral, with a

Via Benzinga

Earnings Scheduled For November 13, 2023 ↗

November 13, 2023

Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter.

Via Benzinga

Earnings Scheduled For August 10, 2023 ↗

August 10, 2023

Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Y-mAbs Therapeutics, Inc. - Common Stock (NQ:YMAB)

Headline News about Y-mAbs Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today